Bribery Policy Novartis

Annual Report 2018 - GSK

Anti-bribery and corruption 30 Environmental matters. Carbon, water and waste 32 Policy, due diligence and outcomes Summary of our principal risks 34 Principal risks and uncertainties 241 Viability statement 44 ... The first step was the buyout of the put option held by Novartis in respect of their minority stake in GSK Consumer Healthcare, which

  Policy, Annual, Report, Annual report, Bribery, Novartis